BrainTrip

BrainTrip occupies a specialized position at the intersection of neurotechnology, health diagnostics, and software. Its differentiation is the conversion of EEG signals into interpretable biomarkers, rather than offering only hardware, wellness content, or general-purpose analytics. The company’s stated applications span early dementia detection, cognitive-health tracking, drug discovery, and personalized medicine. The BrainTrip Dementia Index is described as a certified medical device already on the market, which gives the business a more clinically oriented profile than many early brain-health applications. Potential comparison groups include digital cognitive-assessment companies, EEG analytics vendors, and clinical neurodiagnostics providers, but assigning specific competitors would exceed the available evidence. BrainTrip’s small employee range and limited disclosed financing indicate an early-stage operating scale, while its medical-device certification and market availability suggest progress beyond pure research. Its potential competitive advantage lies in combining neuroscience, machine learning, and scalable EEG analysis for settings where conventional dementia assessment may be difficult to access, including developing countries.

BrainTrip was founded on Jan 8, 2019 and recorded one identified funding event: non-equity assistance announced on Mar 1, 2020, led by Fast Track Malmo. The company’s product scope nevertheless shows a progression from core EEG biomarker generation toward applied diagnostic and research workflows. CogniScore is positioned as an EEG-based cognitive health tracker for detecting cognitive decline or dementia, while the NeuroAI Platform extends the underlying analysis toward large-scale data processing, drug discovery, and personalized medicine. BrainTrip also states that its BrainTrip Dementia Index is certified as a medical device and available on the market, marking a significant commercialization inflection point compared with a laboratory-only system. The company reported an employee range of one to ten and is seeking additional team members and collaborators, indicating that growth remains capability-led and relatively small in scale. The Nov 12, 2025 Seed Winner recognition provides a recent visibility milestone, but there is insufficient evidence to quantify sales growth, geographic expansion, hiring volume, or clinical adoption.